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The Growing Importance of Diabetes
Screening
A
classic report by T. Franklin Wil-
liamsetal.(1)in1967documented
glaring deﬁciencies in diabetes care
that went largely uncorrected for the next
30 years. It is only in the last 10 years that
we have seen substantial and sustained
improvementinbasicaspectsofcaresuch
as glycemic control, blood pressure con-
trol, and lipid control (2). Since 1995,
there have been substantial and sustained
improvementsinglucose,bloodpressure,
and lipid control in adults with diabetes,
andinsomereportsfrommedicalgroups,
A1C is now 7.0%, mean SBP 128
mmHg, and mean LDL 90 mg/dl (3).
The increased likelihood that those with
diabetes will receive adequate treatment
increases the importance of early deten-
tion of diabetes through screening for di-
abetes and pre-diabetes.
However, in the last decade sobering
data have also emerged that indicate that
more intensive control is not necessarily
better. The hope that normalization of
glucose in those with diabetes would vir-
tually abolish the increased cardiovascu-
lar risk associated with type 2 diabetes is
vanishing. Rather than conﬁrm expected
beneﬁts, recent trials instead provide a
most unwelcome quantiﬁcation of the
risks of intensive glycemic control, in-
cluding high treatment costs, increased
risk of severe hypoglycemia, substantial
weight gain, and even, in the Action to
ControlCardiovascularRiskinDiabetes
(ACCORD) trial, an increased risk of
death (4–6). These sobering and unex-
pected data have far reaching implica-
tions that will take years to appreciate.
However, it is immediately apparent
that more attention needs to be devoted
toprimarypreventionoftype2diabetes
and to early identiﬁcation of cases of
diabetes and its insidious progenitor,
pre-diabetes.
Our recent success in achieving rea-
sonable levels of glycemic control, and
emergingdatathatmoreintensivecontrol
is not necessarily better, clearly indicate
the need for more effective screening for
and primary prevention of diabetes.
Those identiﬁed with pre-diabetes may
beneﬁt from lifestyle or pharmacological
intervention that prevents or delays the
onset of diabetes.
Critique of Chatterjee et al.
InthisissueofDiabetesCare,Chatterjeeet
al. (7) report that population-based dia-
betes screening may be cost saving. This
seemslikeverygoodnews,andoneimag-
ines that data such as these might create
some momentum for health plans to en-
dorse a policy of more widespread diabe-
tes screening. But before acting on these
data, we must carefully examine the de-
sign and conduct of the study, and the
assumptions that underlie the model’s
cost-saving conclusion.
In the analysis presented, volunteer
participants aged 40–74 years without a
prior diagnosis of diabetes were recruited
for diabetes screening. Participants aver-
aged 48 years of age with a BMI of 30
kg/m
2; 55% were African American. Mul-
tiple nonfasting testing strategies were in-
vestigated at an initial visit. Nonfasting
testswerechosenduetoconvenienceand
the ability to administer tests without
prior planning. At a second visit, partici-
pants had a diagnostic 75-g oral glucose
tolerancetest.Pre-diabetes(impairedglu-
cosetolerance[IGT]and/orimpairedfast-
ing glucose [IFG]) was identiﬁed in
19.5% of participants and diabetes in
4.9%. Thus, combining diabetes and pre-
diabetes, nearly one-quarter of the popu-
lation was identiﬁed for possible
intervention. Costs for screening are tal-
lied, and cost savings resulting from early
detection are proposed. Screening is
found to be cost saving from a health sys-
tem perspective and nearly cost neutral
from a societal perspective.
Unfortunately, several considerations
makeitunlikelythattheseﬁndingscanbe
replicated in primary care settings. First,
the age, racial composition, and BMI of
the sample indicate that the population
was at high risk for diabetes and pre-
diabetes.Moreover,theuseofvolunteers,
rather than a well-deﬁned practice-based
population, inﬂates the rate of diabetes
and pre-diabetes detected, because those
who volunteer for screening are likely to
do so due to personal concerns of higher
diabetes risk. Previous efforts at practice-
based screening for diabetes have found
fewer candidates for intervention (8).
The authors provide a well-detailed
derivation of screening costs, and treat-
ment costs are derived from nationally
representative sources. However, their
projected cost savings rely on an assumed
10% cost reduction from early detection
and treatment. This assumption is largely
speculative, and the authors demonstrate
that their results are highly sensitive to
this assumption. This ﬁnding is also in-
consistent with the literature examining
the costs of diabetes care, which has doc-
umented increased costs associated with
diabetes care management (9,10). Several
cost-effectiveness analyses have shown
that while cost-effective, more intensive
diabetes care is not typically cost saving
(11–13).
Consistency with American Diabetes
Association screening
recommendations
At ﬁrst glance, the ﬁndings of Chatterjee
etal.(7)mayappeartocontradictcurrent
guidelinesoftheAmericanDiabetesAsso-
ciation(ADA),whichrecommendscreen-
ing adults age 45 years and older every 3
years (14). However, with further consid-
eration, it is clear that their approach is
consistent with clinical guidelines that
recommend periodic screening for high-
risk populations.
ADArecommendstestingfordiabetes
and pre-diabetes among all individuals
age 45 years and older and also among
adultswithBMI25kg/m
2whohavead-
ditionalriskfactorsincludingphysicalin-
activity, a ﬁrst-degree relative with
diabetes, being a member of a high-risk
ethnicpopulation,andhavingahistoryof
gestationaldiabetes,polycysticovarysyn-
drome, or one of several clinical risk fac-
tors such as hypertension, HDL 35 mg/
dl, triglycerides 250 mg/dl, A1C
5.7%, IGT, IFG, or cardiovascular dis-
ease. If results are normal, screening
should be repeated at 3-year intervals,
with consideration of more frequent test-
ing depending on initial results and risk
status. Separate testing criteria are pro-
posed for pregnant women and for
children.
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on expert recommendation, in the ab-
senceofdeﬁnitiverandomizedclinicaltri-
als examining population-based
screening. Clearly, diabetes and pre-
diabetes are common and costly chronic
diseases that are increasing in prevalence
and impose a signiﬁcant public health
burden (15). The long presymptomatic
phase, the availability of testing, and the
ability of interventions to reduce the pro-
gression from pre-diabetes to diabetes
and to reduce the risk of complication
fromdiabetes,supporttheclinicalrecom-
mendations (16). Other advisory groups
may require more strict evidence to guide
screening for diabetes and pre-diabetes.
For example the U.S. Preventive Services
Task Force (USPSTF) recommends test-
ing only during hypertension visits
(blood pressure 135/80 mmHg) on the
basis that strong evidence exists only for
increased cardiovascular risk among peo-
ple with diabetes (17).
A recent cost-effectiveness analysis of
alternative sequential screening strategies
in a representative U.S. population also
supportstheADA’sguidelines.Kahnetal.
(18) show that screening adults age 45
years and older every 3 years resulted in a
91% increase in quality of life-years
gained compared with annual screening
among adults with hypertension (blood
pressure 140/90 mmHg). Kahn et al.
also identify a main limitation for ran-
domized trials of screening: Even a trial
including 650,000 participants followed
over50yearswouldprobablyfailtoshow
a difference among strategies. Thus,
screening recommendations may need to
be based on a variety of study designs in-
cluding simulation studies.
Summary
TheworkofChatterjeeetal.(7)andKahn
et al. (18), along with other recent re-
ports, provide important new informa-
tion on the merits and costs of screening
for diabetes. Although the case for type 2
diabetes screening being cost saving is a
dubious one, these new data conﬁrm that
screeninghigh-riskpatientsfordiabetesis
a reasonable clinical strategy and not pro-
hibitively expensive. Thus, these data can
be interpreted as providing additional
support for the current ADA type 2 dia-
betes screening recommendations. Con-
ducting a deﬁnitive randomized trial to
support or refute diabetes screening rec-
ommendations is increasingly unfeasible
in the U.S. or most of Europe for a variety
of reasons. Instead, we will be left with a
large number of studies of varied design
and conduct, and we must infer from
theirsometimesincongruentresultsarea-
sonable approach to diabetes screening.
Several questions come up in this regard.
First, to what extent will the recent en-
dorsement of new A1C thresholds for the
diagnosis of diabetes and pre-diabetes re-
shape the diabetes screening landscape
(14)? Second will the new emphasis on
comparative effectiveness, and the use of
sophisticated instrumental variable or
propensity score analytic strategies, in-
crease the conﬁdence we have in the re-
sultsoflargeobservationalstudies?Third,
will revised simulation models that in-
clude new information reﬂecting the re-
cent ﬁndings of ACCORD, Action in
Diabetes and Vascular Disease: Preterax
andDiamicronMRControlledEvaluation
(ADVANCE), and Veterans Affairs Diabe-
tes Trial (VADT) change the calculus on
cost-effectiveness of screening? Fourth,
can organizations including ADA and
USPSTF reach a common, practical un-
derstanding of what constitutes a reason-
able approach to diabetes screening, so
thatprimarycareproviderswillhaveone,
instead of multiple guidelines to follow?
And ﬁnally, how will new genetic and
other novel predictors of macrovascular
or microvascular complications inform
future diabetes screening strategies?
Weliveinexcitingtimes,andourcol-
laborative effort to develop more effective
and efﬁcient diabetes screening strategies
in conjunction with the development of
improved primary preventive strategies is
a signature challenge now faced by the
worldwide diabetes community.
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